Catalent Pharma Solutions

Catalent Pharma Solutions is a leading strategic partner for biosimiliar development with innovative solutions, unique technologies and integrated services which enable clients to achieve more and better products to clinic, faster. Catalent’s proprietary GPEx® technology creates stable, high-yielding mammalian cell lines with high speed and efficiency which can accelerate drug development projects to clinic in one-third the time of traditional approaches. This technology, when combined with Catalent’s Triplet-Fix™ codon optimization and integrated analytical development, fill finish and clinical supply services offer expertise and flexibility to create tailored solutions for your project needs. GPEx uses a retrovector technology that ensures the stable transduction of targeted cells, approaching 100% efficiency. This level of efficiency eliminates the requirement for selectable markers and stable clonal cell lines are produced in less than five months for any mammalian cell line or in-house Master. Catalent GPEx-engineered cell lines can assist in all stages of drug development, from early feasibility studies, to clinical manufacturing, to commercial scale production, and have supported the launch of five commercial biosimilar projects (four of which are antibodies), with many more in clinical trials. www.catalent.com

---

---